Hamilton Researchers find blood thinner reduces risk of death after non-cardiac surgery

Researchers have discovered that a blood-thinning drug, dabigatran, can significantly reduce the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery. Every year, around eight million people in the world develop a condition called myocardial injury after non-cardiac surgery (MINS), which

Continue Reading

FDA approves investigational new drug application for treatment of mucopolysaccharidosis type IIIA

Swedish Biopharmaceutical company, Swedish Orphan Biovitrum AB has announced that the FDA has issued a “study may proceed” letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003 for the treatment of mucopolysaccharidosis type IIIA. In addition, SOBI003 was granted Fast Track status by the

Continue Reading

Children’s Hospital Colorado preparing 25 new cancer trials after “breakthrough” law signed

Doctors at Children’s Hospital Colorado are hoping to launch as many as 25 new clinical trials in the next six months following a recently signed federal law opened the floodgates to test experimental cancer drugs for children. “The paediatric oncology community is really excited,” said Dr. Lia Gore, the director of Children’s Center for Cancer

Continue Reading